OVID on XNAS, Health Care, Ovid Therapeutics Inc., job postings
Measures activity, not value. Not investment advice.
Short interest jumped to 21.2M shares, 43 times a year earlier, while revenue fell 78%.
WatchShares up 80% in 12 months, short interest 9.6% of shares
BadNet loss of $43.1M over 12 months on $1.5M revenue
Written by AI from the data on this page, 22 Nov 2026. Not investment advice.
Profile and fundamentals
From its SEC filings, 12 months to 30 Sep 2026
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.
expected around 17 Mar 2027 (an estimate: a year ago it reported on 18 Mar 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: revenue $0, net loss $20.8M.
31 Dec 2021RevenueNet incomeNet losstallest bar $26.0M30 Sep 2026
See the numbers
Quarter to
Revenue
Net income
30 Sep 2026
$0
-$20.8M
30 Jun 2026
$733K
-$15.0M
31 Mar 2026
$0
-$17.0M
31 Dec 2025
$718K
$9.7M
30 Sep 2025
$132K
-$12.2M
30 Jun 2025
$6.3M
-$4.7M
31 Mar 2025
$130K
-$10.2M
31 Dec 2024
$76K
-$9.3M
30 Sep 2024
$173K
-$14.0M
30 Jun 2024
$169K
$8.5M
31 Mar 2024
$148K
-$11.7M
31 Dec 2023
–
-$15.3M
30 Sep 2023
$109K
-$11.3M
30 Jun 2023
$75K
-$12.4M
31 Mar 2023
$66K
-$13.4M
31 Dec 2022
–
-$11.5M
30 Sep 2022
$11K
-$12.0M
30 Jun 2022
$0
-$14.6M
31 Mar 2022
$1.4M
-$16.1M
31 Dec 2021
$0
-$26.0M
Fundamentals, 12 months to 30 Sep 2026
Measure
Latest
Year before
Peer median
RevenueiSales over the last 12 months reported.
$1.5M
$6.6M
Revenue growthiRevenue of the last 12 months compared with the 12 months before.
-78%
+11%
Net incomeiProfit after all costs and taxes over the last 12 months reported. Negative is a loss.
-$43.1M
-$36.3M
EPS (diluted)iEarnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split).
–
–
Gross marginiWhat is left of each dollar of sales after the direct cost of making the product or service.
–
–
73.2%
Operating marginiOperating income as a share of sales: profit from the business before interest and taxes.
–
-618%
-25.0%
Net marginiNet income as a share of sales: what the owners keep of each dollar sold.
–
-550%
-18.2%
Return on equityiNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money.
-35.4%
-58.8%
Free cash flowiCash from operations minus capital spending over the last 12 months: cash the business produced.
–
–
CashiCash, cash equivalents and short-term investments on the latest balance sheet.
$161.4M
$25.6M
DebtiShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted.
$0
$0
Net debtiDebt minus cash. Negative means the company holds more cash than it owes (net cash).
-$161.4M (net cash)
-$25.6M
Debt to equityiDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative.
0.0
0.0
Book value per shareiShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding.
$1.05
P/EiPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss.
loss
19.3
P/SiPrice to sales: market cap divided by revenue of the last 12 months.
286
5.0
EV/SalesiEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months.
175
5.0
P/BiPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative.
2.1
2.0
Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.
Peers nearest by market cap, its own industry first
Institutional holders iThe number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.
-1.6%
127 13F filers vs 129
Institutional ownership iShares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.
79%
148.4M shares held by 13F filers (30 Sep 2026) of 188.7M outstanding (4 Nov 2026)
Short interest iShares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.
9.6%
18.1M shares sold short (30 Oct 2026) of 188.7M outstanding (4 Nov 2026)
Days to cover iShort interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.
8.2
18.1M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it
Short interest change iHow the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.
+0.4%
18.1M shares sold short in the report before, 18.1M on 30 Oct 2026
Short sale volume iShare of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.
77%
77% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 48%
Open jobs iJob postings open on the company's own careers site today, where we track it. Blank when we do not track this company's careers site yet.
3
Tracked since 21 Nov 2026
Open jobs change iHow the number of open job postings changed over the last 30 days: total hiring demand, any job, any country. Shown only once we have tracked the company for 30 days.
–
Tracking started 21 Nov 2026; the change shows after 30 days.
News iArticles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.
6
6 articles in the last 7 days; its usual week has 2 (the median of the 26 weeks before).
News vs usual iArticles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.
3.0×
6 articles in the last 7 days; its usual week has 2.
Unusual now sharp changes in the last 90 days, compared with its own past
Short interest 21.2M, 43× a year earlier
Price $2.20 on 20 Nov 2026, +80% over 12 months (12-month range $1.22 to $2.96)
Sharp change
8-K and other filings
Lobbying filing
Insider net buying (open market). Insiders sold a net $29K in the last 12 months (the 12 months before: -$170).H-1B/E-3 applications certified. H-1B/E-3 applications certified: 0 published in the last 12 months.Revenue per quarter. Revenue $0 in the latest quarter, -100% on a year earlier.Capital spending per quarter. Capital spending $0 in the latest quarter.Institutional holders (13F filers). 127 13F filers reported holding it in the latest 13F quarter, +61% on a year earlier.Lobbying spend. Lobbying spend: $0 published in the last 12 months.
Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: federal obligations, workers in warn layoff notices.
Quarter ended 30 Jun 2021: $0; public on 10 Aug 2022
Quarter ended 30 Sep 2021: $0, -100% on a year earlier; public on 9 Nov 2022
Quarter ended 31 Dec 2021: $0, -100% on a year earlier; public on 16 Mar 2022
Quarter ended 31 Mar 2022: $1.4M, -99% on a year earlier; public on 11 May 2022
Quarter ended 30 Jun 2022: $0; public on 10 Aug 2022
Quarter ended 30 Sep 2022: $11K; public on 9 Nov 2022
Quarter ended 31 Mar 2023: $66K, -95% on a year earlier; public on 6 May 2023
Quarter ended 30 Jun 2023: $75K; public on 5 Aug 2023
Quarter ended 30 Sep 2023: $109K, +882% on a year earlier; public on 4 Nov 2023
Quarter ended 31 Mar 2024: $148K, +124% on a year earlier; public on 15 May 2024
Quarter ended 30 Jun 2024: $169K, +125% on a year earlier; public on 14 Aug 2024
Quarter ended 30 Sep 2024: $173K, +59% on a year earlier; public on 13 Nov 2024
Quarter ended 31 Dec 2024: $76K; public on 12 Mar 2025
Quarter ended 31 Mar 2025: $130K, -12% on a year earlier; public on 14 May 2025
Quarter ended 30 Jun 2025: $6.3M, +3611% on a year earlier; public on 14 Aug 2025
Quarter ended 30 Sep 2025: $132K, -24% on a year earlier; public on 13 Nov 2025
Quarter ended 31 Dec 2025: $718K, +845% on a year earlier; public on 19 Mar 2026
Quarter ended 31 Mar 2026: $0, -100% on a year earlier; public on 13 May 2026
Quarter ended 30 Jun 2026: $733K, -88% on a year earlier; public on 14 Aug 2026
Quarter ended 30 Sep 2026: $0, -100% on a year earlier; public on 11 Nov 2026
Capital spending per quarter
Quarter ended 31 Mar 2022: $46K, +299% on a year earlier; public on 11 May 2022
Quarter ended 30 Sep 2022: $19K, +77% on a year earlier; public on 9 Nov 2022
Quarter ended 31 Dec 2022: $120K; public on 14 Mar 2023
Quarter ended 31 Mar 2023: $14K, -70% on a year earlier; public on 6 May 2023
Quarter ended 30 Jun 2023: $8K; public on 5 Aug 2023
Quarter ended 30 Sep 2023: $5K, -72% on a year earlier; public on 4 Nov 2023
Quarter ended 31 Dec 2023: $14K, -89% on a year earlier; public on 9 Mar 2024
Quarter ended 31 Mar 2024: $19K, +40% on a year earlier; public on 15 May 2024
Quarter ended 31 Mar 2025: $0, -100% on a year earlier; public on 14 May 2025
Quarter ended 30 Jun 2025: $0; public on 14 Aug 2025
Quarter ended 30 Sep 2025: $0; public on 13 Nov 2025
Quarter ended 31 Dec 2025: $0; public on 19 Mar 2026
Institutional holders (13F filers)
31 Dec 2021 report: 65; public on 14 Feb 2022
31 Mar 2022 report: 59; public on 16 May 2022
30 Jun 2022 report: 54; public on 15 Aug 2022
30 Sep 2022 report: 55; public on 14 Nov 2022
31 Dec 2022 report: 58; public on 14 Feb 2023
31 Mar 2023 report: 57; public on 15 May 2023
30 Jun 2023 report: 65; public on 14 Aug 2023
30 Sep 2023 report: 60; public on 14 Nov 2023
31 Dec 2023 report: 69; public on 14 Feb 2024
31 Mar 2024 report: 78; public on 15 May 2024
30 Jun 2024 report: 71; public on 14 Aug 2024
30 Sep 2024 report: 72; public on 14 Nov 2024
31 Dec 2024 report: 82; public on 14 Feb 2025
31 Mar 2025 report: 79; public on 15 May 2025
30 Jun 2025 report: 68; public on 14 Aug 2025
30 Sep 2025 report: 79; public on 14 Nov 2025
31 Dec 2025 report: 83; public on 17 Feb 2026
31 Mar 2026 report: 100; public on 15 May 2026
30 Jun 2026 report: 129; public on 14 Aug 2026
30 Sep 2026 report: 127; public on 16 Nov 2026
Lobbying spend
Quarter from 1 Jan 2022: $20K published
Quarter from 1 Apr 2022: $20K published
Quarter from 1 Jul 2022: $20K published
Quarter from 1 Oct 2022: $20K published
Quarter from 1 Jan 2023: $20K published
Quarter from 1 Apr 2023: $20K published
What is unusual now
Made public in the last 90 days: it had 21.2M shares sold short in the 15 Sep 2026 report, 43× the same report last year; it also had 21.6M shares sold short in the 14 Aug 2026 report, 14× the same report last year. 3 sharp changes in all.
Short interest spike: had 21.2M shares sold short in the 15 Sep 2026 report, 43× the same report last year Public on 25 Sep 2026.
Reported lobbying spend: $20K in Q1 2023, $20K in Q4 2022. Rows are lobbying firms hired or let go; amounts are reported per quarter, not per firm here.
Two or more unrelated kinds of records unusual within 30 days
18 Nov 2025confirmed
Confirmed across sources Institutional holdings and Short interest and volume
Ovid Therapeutics(OVID): saw 25 13F filers open a new position in the quarter ended 30 Sep 2025, 3.6× the same quarter last year, while it had 4.8M shares sold short in the 15 Jan 2026 report, 6.8× the same report last year. Two unrelated kinds of activity within 126 days.
Short interest and volume: Short interest spike, became public on 25 Oct 2025
Institutional holdings: Many funds opening a new position, became public on 14 Nov 2025
Short interest and volume: Short interest spike, became public on 13 Nov 2025
Short interest and volume: Short interest spike, became public on 26 Nov 2025
Short interest and volume: Short interest spike, became public on 10 Dec 2025
Short interest and volume: Short interest spike, became public on 25 Dec 2025
Short interest and volume: Short interest spike, became public on 13 Jan 2026
Short interest and volume: Short interest spike, became public on 28 Jan 2026
Short interest and volume: Short interest spike, became public on 11 Feb 2026
Short interest and volume: Short interest spike, became public on 26 Feb 2026
The quarter ended 30 Sep 2025 against the 8 quarters before it.
this quarterearliernormal: 10.5See the evidence (10 changes)
Short interest and volume: Short interest spike became public on 25 Oct 2025
Ovid Therapeutics had 3.8M shares sold short in the 15 Oct 2025 report, 6.3× the same report last year.
This period
3.8M (the 15 Oct 2025 report)
Normal report (median of 24 earlier)
1.0M
Typical spread (median absolute deviation)
300K
How far from its usual level
+6.3
Same report last year
607K
History used
2,847 days
the 15 Oct 2025 report24 earlier reportsnormal: 1.0M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Institutional holdings: Many funds opening a new position became public on 14 Nov 2025
Ovid Therapeutics saw 25 13F filers open a new position in the quarter ended 30 Sep 2025, 3.6× the same quarter last year.
This period
25 (the quarter ended 30 Sep 2025)
Normal quarter (median of 8 earlier)
10.5
Typical spread (median absolute deviation)
1.5
How far from its usual level
+4.8
Same quarter last year
7
History used
3,014 days
the quarter ended 30 Sep 20258 earlier quartersnormal: 10.5
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.
Short interest and volume: Short interest spike became public on 13 Nov 2025
Ovid Therapeutics had 3.5M shares sold short in the 31 Oct 2025 report, 5.1× the same report last year.
This period
3.5M (the 31 Oct 2025 report)
Normal report (median of 24 earlier)
1.1M
Typical spread (median absolute deviation)
306K
How far from its usual level
+5.3
Same report last year
680K
History used
2,863 days
the 31 Oct 2025 report24 earlier reportsnormal: 1.1M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 26 Nov 2025
Ovid Therapeutics had 3.5M shares sold short in the 14 Nov 2025 report, 4.6× the same report last year.
This period
3.5M (the 14 Nov 2025 report)
Normal report (median of 24 earlier)
1.1M
Typical spread (median absolute deviation)
377K
How far from its usual level
+4.2
Same report last year
757K
History used
2,877 days
the 14 Nov 2025 report24 earlier reportsnormal: 1.1M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 10 Dec 2025
Ovid Therapeutics had 3.9M shares sold short in the 28 Nov 2025 report, 5.2× the same report last year.
This period
3.9M (the 28 Nov 2025 report)
Normal report (median of 24 earlier)
1.2M
Typical spread (median absolute deviation)
363K
How far from its usual level
+4.9
Same report last year
740K
History used
2,891 days
the 28 Nov 2025 report24 earlier reportsnormal: 1.2M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 25 Dec 2025
Ovid Therapeutics had 4.2M shares sold short in the 15 Dec 2025 report, 4.4× the same report last year.
This period
4.2M (the 15 Dec 2025 report)
Normal report (median of 24 earlier)
1.2M
Typical spread (median absolute deviation)
363K
How far from its usual level
+5.5
Same report last year
948K
History used
2,908 days
the 15 Dec 2025 report24 earlier reportsnormal: 1.2M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 13 Jan 2026
Ovid Therapeutics had 4.4M shares sold short in the 31 Dec 2025 report, 6.3× the same report last year.
This period
4.4M (the 31 Dec 2025 report)
Normal report (median of 24 earlier)
1.3M
Typical spread (median absolute deviation)
373K
How far from its usual level
+5.7
Same report last year
692K
History used
2,924 days
the 31 Dec 2025 report24 earlier reportsnormal: 1.3M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 28 Jan 2026
Ovid Therapeutics had 4.8M shares sold short in the 15 Jan 2026 report, 6.8× the same report last year.
This period
4.8M (the 15 Jan 2026 report)
Normal report (median of 24 earlier)
1.3M
Typical spread (median absolute deviation)
338K
How far from its usual level
+7.0
Same report last year
706K
History used
2,939 days
the 15 Jan 2026 report24 earlier reportsnormal: 1.3M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 11 Feb 2026
Ovid Therapeutics had 4.8M shares sold short in the 30 Jan 2026 report, 5.5× the same report last year.
This period
4.8M (the 30 Jan 2026 report)
Normal report (median of 24 earlier)
1.4M
Typical spread (median absolute deviation)
427K
How far from its usual level
+5.4
Same report last year
884K
History used
2,954 days
the 30 Jan 2026 report24 earlier reportsnormal: 1.4M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 26 Feb 2026
Ovid Therapeutics had 5.2M shares sold short in the 13 Feb 2026 report, 5.2× the same report last year.
This period
5.2M (the 13 Feb 2026 report)
Normal report (median of 24 earlier)
1.6M
Typical spread (median absolute deviation)
563K
How far from its usual level
+4.4
Same report last year
991K
History used
2,968 days
the 13 Feb 2026 report24 earlier reportsnormal: 1.6M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.
15 Aug 2023confirmed
Confirmed across sources Institutional holdings and Short interest and volume
Ovid Therapeutics(OVID): saw 21 13F filers open a new position in the quarter ended 30 Jun 2023, 3.5× the same quarter last year, while it had 2.1M shares sold short in the 15 Nov 2023 report, 7.4× the same report last year. Two unrelated kinds of activity within 168 days.
Short interest and volume: Short interest spike, became public on 13 Jul 2023
Short interest and volume: Short interest spike, became public on 26 Jul 2023
Institutional holdings: Many funds opening a new position, became public on 14 Aug 2023
Short interest and volume: Short interest spike, became public on 10 Aug 2023
Short interest and volume: Short interest spike, became public on 25 Aug 2023
Short interest and volume: Short interest spike, became public on 13 Sep 2023
Short interest and volume: Short interest spike, became public on 27 Sep 2023
Short interest and volume: Short interest spike, became public on 12 Oct 2023
Short interest and volume: Short interest spike, became public on 25 Oct 2023
Short interest and volume: Short interest spike, became public on 10 Nov 2023
Short interest and volume: Short interest spike, became public on 28 Nov 2023
Short interest and volume: Short interest spike, became public on 12 Dec 2023
Short interest and volume: Short interest spike, became public on 28 Dec 2023
The quarter ended 30 Jun 2023 against the 8 quarters before it.
this quarterearliernormal: 7.5See the evidence (13 changes)
Short interest and volume: Short interest spike became public on 13 Jul 2023
Ovid Therapeutics had 1.8M shares sold short in the 30 Jun 2023 report, 5.0× the same report last year.
This period
1.8M (the 30 Jun 2023 report)
Normal report (median of 24 earlier)
279K
Typical spread (median absolute deviation)
45K
How far from its usual level
+23.2
Same report last year
366K
History used
2,009 days
the 30 Jun 2023 report24 earlier reportsnormal: 279K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 26 Jul 2023
Ovid Therapeutics had 1.8M shares sold short in the 14 Jul 2023 report, 5.4× the same report last year.
This period
1.8M (the 14 Jul 2023 report)
Normal report (median of 24 earlier)
279K
Typical spread (median absolute deviation)
45K
How far from its usual level
+23.1
Same report last year
341K
History used
2,023 days
the 14 Jul 2023 report24 earlier reportsnormal: 279K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Institutional holdings: Many funds opening a new position became public on 14 Aug 2023
Ovid Therapeutics saw 21 13F filers open a new position in the quarter ended 30 Jun 2023, 3.5× the same quarter last year.
This period
21 (the quarter ended 30 Jun 2023)
Normal quarter (median of 8 earlier)
7.5
Typical spread (median absolute deviation)
2
How far from its usual level
+4.5
Same quarter last year
6
History used
2,191 days
the quarter ended 30 Jun 20238 earlier quartersnormal: 7.5
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.
Short interest and volume: Short interest spike became public on 10 Aug 2023
Ovid Therapeutics had 1.8M shares sold short in the 31 Jul 2023 report, 6.1× the same report last year.
This period
1.8M (the 31 Jul 2023 report)
Normal report (median of 24 earlier)
279K
Typical spread (median absolute deviation)
45K
How far from its usual level
+23.1
Same report last year
301K
History used
2,040 days
the 31 Jul 2023 report24 earlier reportsnormal: 279K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 25 Aug 2023
Ovid Therapeutics had 1.8M shares sold short in the 15 Aug 2023 report, 6.6× the same report last year.
This period
1.8M (the 15 Aug 2023 report)
Normal report (median of 24 earlier)
279K
Typical spread (median absolute deviation)
50K
How far from its usual level
+21.0
Same report last year
281K
History used
2,055 days
the 15 Aug 2023 report24 earlier reportsnormal: 279K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 13 Sep 2023
Ovid Therapeutics had 2.1M shares sold short in the 31 Aug 2023 report, 7.2× the same report last year.
This period
2.1M (the 31 Aug 2023 report)
Normal report (median of 24 earlier)
280K
Typical spread (median absolute deviation)
55K
How far from its usual level
+22.1
Same report last year
288K
History used
2,071 days
the 31 Aug 2023 report24 earlier reportsnormal: 280K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 27 Sep 2023
Ovid Therapeutics had 2.0M shares sold short in the 15 Sep 2023 report, 7.3× the same report last year.
This period
2.0M (the 15 Sep 2023 report)
Normal report (median of 24 earlier)
280K
Typical spread (median absolute deviation)
58K
How far from its usual level
+20.2
Same report last year
278K
History used
2,086 days
the 15 Sep 2023 report24 earlier reportsnormal: 280K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 12 Oct 2023
Ovid Therapeutics had 2.1M shares sold short in the 29 Sep 2023 report, 7.3× the same report last year.
This period
2.1M (the 29 Sep 2023 report)
Normal report (median of 24 earlier)
283K
Typical spread (median absolute deviation)
66K
How far from its usual level
+18.2
Same report last year
283K
History used
2,100 days
the 29 Sep 2023 report24 earlier reportsnormal: 283K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 25 Oct 2023
Ovid Therapeutics had 2.0M shares sold short in the 13 Oct 2023 report, 6.8× the same report last year.
This period
2.0M (the 13 Oct 2023 report)
Normal report (median of 24 earlier)
286K
Typical spread (median absolute deviation)
72K
How far from its usual level
+15.7
Same report last year
288K
History used
2,114 days
the 13 Oct 2023 report24 earlier reportsnormal: 286K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 10 Nov 2023
Ovid Therapeutics had 2.0M shares sold short in the 31 Oct 2023 report, 7.2× the same report last year.
This period
2.0M (the 31 Oct 2023 report)
Normal report (median of 24 earlier)
286K
Typical spread (median absolute deviation)
75K
How far from its usual level
+15.6
Same report last year
278K
History used
2,132 days
the 31 Oct 2023 report24 earlier reportsnormal: 286K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 28 Nov 2023
Ovid Therapeutics had 2.1M shares sold short in the 15 Nov 2023 report, 7.4× the same report last year.
This period
2.1M (the 15 Nov 2023 report)
Normal report (median of 24 earlier)
305K
Typical spread (median absolute deviation)
101K
How far from its usual level
+12.2
Same report last year
288K
History used
2,147 days
the 15 Nov 2023 report24 earlier reportsnormal: 305K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 12 Dec 2023
Ovid Therapeutics had 2.3M shares sold short in the 30 Nov 2023 report, 8.5× the same report last year.
This period
2.3M (the 30 Nov 2023 report)
Normal report (median of 24 earlier)
368K
Typical spread (median absolute deviation)
165K
How far from its usual level
+7.9
Same report last year
271K
History used
2,162 days
the 30 Nov 2023 report24 earlier reportsnormal: 368K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 28 Dec 2023
Ovid Therapeutics had 2.5M shares sold short in the 15 Dec 2023 report, 8.7× the same report last year.
This period
2.5M (the 15 Dec 2023 report)
Normal report (median of 24 earlier)
498K
Typical spread (median absolute deviation)
294K
How far from its usual level
+4.5
Same report last year
283K
History used
2,177 days
the 15 Dec 2023 report24 earlier reportsnormal: 498K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.
18 Feb 2020confirmed
Confirmed across sources Institutional holdings and Lobbying
Ovid Therapeutics(OVID): registered for federal lobbying for the first time in our data (The Kpm Group Dc Llc), while it saw 25 13F filers open a new position in the quarter ended 31 Dec 2019, 3.1× the same quarter last year. Two unrelated kinds of activity within 28 days.
Lobbying: First lobbying registration, became public on 21 Jan 2020
Institutional holdings: Many funds opening a new position, became public on 14 Feb 2020
The quarter ended 31 Dec 2019 against the 8 quarters before it.
this quarterearliernormal: 8See the evidence (2 changes)
Lobbying: First lobbying registration became public on 21 Jan 2020
Ovid Therapeutics registered for federal lobbying for the first time in our data (The Kpm Group Dc Llc).
"First" means first in our data: it fires only when the source's history began at least 365 days earlier.
Institutional holdings: Many funds opening a new position became public on 14 Feb 2020
Ovid Therapeutics saw 25 13F filers open a new position in the quarter ended 31 Dec 2019, 3.1× the same quarter last year.
This period
25 (the quarter ended 31 Dec 2019)
Normal quarter (median of 8 earlier)
8
Typical spread (median absolute deviation)
1
How far from its usual level
+5.7
Same quarter last year
8
History used
914 days
the quarter ended 31 Dec 20198 earlier quartersnormal: 8
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.
Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.
Timeline
Changes and notable records, by the date each became public
25 Sep 2026Short interest and volume change
had 21.2M shares sold short in the 15 Sep 2026 report, 43× the same report last year.
Same report last year: 489K; its normal report is 5.3M.
See the evidence
This period
21.2M (the 15 Sep 2026 report)
Normal report (median of 24 earlier)
5.3M
Typical spread (median absolute deviation)
2.5M
How far from its usual level
+4.2
Same report last year
489K
History used
3,182 days
the 15 Sep 2026 report24 earlier reportsnormal: 5.3M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 20.7M shares sold short in the 31 Aug 2026 report, 16× the same report last year.
Same report last year: 1.3M; its normal report is 5.1M.
See the evidence
This period
20.7M (the 31 Aug 2026 report)
Normal report (median of 24 earlier)
5.1M
Typical spread (median absolute deviation)
2.6M
How far from its usual level
+4.0
Same report last year
1.3M
History used
3,167 days
the 31 Aug 2026 report24 earlier reportsnormal: 5.1M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 21.6M shares sold short in the 14 Aug 2026 report, 14× the same report last year.
Same report last year: 1.5M; its normal report is 5.0M.
See the evidence
This period
21.6M (the 14 Aug 2026 report)
Normal report (median of 24 earlier)
5.0M
Typical spread (median absolute deviation)
2.7M
How far from its usual level
+4.1
Same report last year
1.5M
History used
3,150 days
the 14 Aug 2026 report24 earlier reportsnormal: 5.0M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 21.5M shares sold short in the 31 Jul 2026 report, 13× the same report last year.
Same report last year: 1.6M; its normal report is 4.8M.
See the evidence
This period
21.5M (the 31 Jul 2026 report)
Normal report (median of 24 earlier)
4.8M
Typical spread (median absolute deviation)
2.7M
How far from its usual level
+4.2
Same report last year
1.6M
History used
3,136 days
the 31 Jul 2026 report24 earlier reportsnormal: 4.8M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 9.3M shares sold short in the 31 Mar 2026 report, 7.7× the same report last year.
Same report last year: 1.2M; its normal report is 2.1M.
See the evidence
This period
9.3M (the 31 Mar 2026 report)
Normal report (median of 24 earlier)
2.1M
Typical spread (median absolute deviation)
1.4M
How far from its usual level
+3.5
Same report last year
1.2M
History used
3,014 days
the 31 Mar 2026 report24 earlier reportsnormal: 2.1M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 5.2M shares sold short in the 13 Feb 2026 report, 5.2× the same report last year.
Same report last year: 991K; its normal report is 1.6M.
See the evidence
This period
5.2M (the 13 Feb 2026 report)
Normal report (median of 24 earlier)
1.6M
Typical spread (median absolute deviation)
563K
How far from its usual level
+4.4
Same report last year
991K
History used
2,968 days
the 13 Feb 2026 report24 earlier reportsnormal: 1.6M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 4.8M shares sold short in the 30 Jan 2026 report, 5.5× the same report last year.
Same report last year: 884K; its normal report is 1.4M.
See the evidence
This period
4.8M (the 30 Jan 2026 report)
Normal report (median of 24 earlier)
1.4M
Typical spread (median absolute deviation)
427K
How far from its usual level
+5.4
Same report last year
884K
History used
2,954 days
the 30 Jan 2026 report24 earlier reportsnormal: 1.4M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 4.8M shares sold short in the 15 Jan 2026 report, 6.8× the same report last year.
Same report last year: 706K; its normal report is 1.3M.
See the evidence
This period
4.8M (the 15 Jan 2026 report)
Normal report (median of 24 earlier)
1.3M
Typical spread (median absolute deviation)
338K
How far from its usual level
+7.0
Same report last year
706K
History used
2,939 days
the 15 Jan 2026 report24 earlier reportsnormal: 1.3M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 4.4M shares sold short in the 31 Dec 2025 report, 6.3× the same report last year.
Same report last year: 692K; its normal report is 1.3M.
See the evidence
This period
4.4M (the 31 Dec 2025 report)
Normal report (median of 24 earlier)
1.3M
Typical spread (median absolute deviation)
373K
How far from its usual level
+5.7
Same report last year
692K
History used
2,924 days
the 31 Dec 2025 report24 earlier reportsnormal: 1.3M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 4.2M shares sold short in the 15 Dec 2025 report, 4.4× the same report last year.
Same report last year: 948K; its normal report is 1.2M.
See the evidence
This period
4.2M (the 15 Dec 2025 report)
Normal report (median of 24 earlier)
1.2M
Typical spread (median absolute deviation)
363K
How far from its usual level
+5.5
Same report last year
948K
History used
2,908 days
the 15 Dec 2025 report24 earlier reportsnormal: 1.2M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 3.9M shares sold short in the 28 Nov 2025 report, 5.2× the same report last year.
Same report last year: 740K; its normal report is 1.2M.
See the evidence
This period
3.9M (the 28 Nov 2025 report)
Normal report (median of 24 earlier)
1.2M
Typical spread (median absolute deviation)
363K
How far from its usual level
+4.9
Same report last year
740K
History used
2,891 days
the 28 Nov 2025 report24 earlier reportsnormal: 1.2M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 3.5M shares sold short in the 14 Nov 2025 report, 4.6× the same report last year.
Same report last year: 757K; its normal report is 1.1M.
See the evidence
This period
3.5M (the 14 Nov 2025 report)
Normal report (median of 24 earlier)
1.1M
Typical spread (median absolute deviation)
377K
How far from its usual level
+4.2
Same report last year
757K
History used
2,877 days
the 14 Nov 2025 report24 earlier reportsnormal: 1.1M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
saw 25 13F filers open a new position in the quarter ended 30 Sep 2025, 3.6× the same quarter last year, while it had 4.8M shares sold short in the 15 Jan 2026 report, 6.8× the same report last year. Two unrelated kinds of activity within 126 days.
See the evidence (10 changes)
Short interest and volume: Short interest spike became public on 25 Oct 2025
Ovid Therapeutics had 3.8M shares sold short in the 15 Oct 2025 report, 6.3× the same report last year.
This period
3.8M (the 15 Oct 2025 report)
Normal report (median of 24 earlier)
1.0M
Typical spread (median absolute deviation)
300K
How far from its usual level
+6.3
Same report last year
607K
History used
2,847 days
the 15 Oct 2025 report24 earlier reportsnormal: 1.0M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Institutional holdings: Many funds opening a new position became public on 14 Nov 2025
Ovid Therapeutics saw 25 13F filers open a new position in the quarter ended 30 Sep 2025, 3.6× the same quarter last year.
This period
25 (the quarter ended 30 Sep 2025)
Normal quarter (median of 8 earlier)
10.5
Typical spread (median absolute deviation)
1.5
How far from its usual level
+4.8
Same quarter last year
7
History used
3,014 days
the quarter ended 30 Sep 20258 earlier quartersnormal: 10.5
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.
Short interest and volume: Short interest spike became public on 13 Nov 2025
Ovid Therapeutics had 3.5M shares sold short in the 31 Oct 2025 report, 5.1× the same report last year.
This period
3.5M (the 31 Oct 2025 report)
Normal report (median of 24 earlier)
1.1M
Typical spread (median absolute deviation)
306K
How far from its usual level
+5.3
Same report last year
680K
History used
2,863 days
the 31 Oct 2025 report24 earlier reportsnormal: 1.1M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 26 Nov 2025
Ovid Therapeutics had 3.5M shares sold short in the 14 Nov 2025 report, 4.6× the same report last year.
This period
3.5M (the 14 Nov 2025 report)
Normal report (median of 24 earlier)
1.1M
Typical spread (median absolute deviation)
377K
How far from its usual level
+4.2
Same report last year
757K
History used
2,877 days
the 14 Nov 2025 report24 earlier reportsnormal: 1.1M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 10 Dec 2025
Ovid Therapeutics had 3.9M shares sold short in the 28 Nov 2025 report, 5.2× the same report last year.
This period
3.9M (the 28 Nov 2025 report)
Normal report (median of 24 earlier)
1.2M
Typical spread (median absolute deviation)
363K
How far from its usual level
+4.9
Same report last year
740K
History used
2,891 days
the 28 Nov 2025 report24 earlier reportsnormal: 1.2M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 25 Dec 2025
Ovid Therapeutics had 4.2M shares sold short in the 15 Dec 2025 report, 4.4× the same report last year.
This period
4.2M (the 15 Dec 2025 report)
Normal report (median of 24 earlier)
1.2M
Typical spread (median absolute deviation)
363K
How far from its usual level
+5.5
Same report last year
948K
History used
2,908 days
the 15 Dec 2025 report24 earlier reportsnormal: 1.2M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 13 Jan 2026
Ovid Therapeutics had 4.4M shares sold short in the 31 Dec 2025 report, 6.3× the same report last year.
This period
4.4M (the 31 Dec 2025 report)
Normal report (median of 24 earlier)
1.3M
Typical spread (median absolute deviation)
373K
How far from its usual level
+5.7
Same report last year
692K
History used
2,924 days
the 31 Dec 2025 report24 earlier reportsnormal: 1.3M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 28 Jan 2026
Ovid Therapeutics had 4.8M shares sold short in the 15 Jan 2026 report, 6.8× the same report last year.
This period
4.8M (the 15 Jan 2026 report)
Normal report (median of 24 earlier)
1.3M
Typical spread (median absolute deviation)
338K
How far from its usual level
+7.0
Same report last year
706K
History used
2,939 days
the 15 Jan 2026 report24 earlier reportsnormal: 1.3M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 11 Feb 2026
Ovid Therapeutics had 4.8M shares sold short in the 30 Jan 2026 report, 5.5× the same report last year.
This period
4.8M (the 30 Jan 2026 report)
Normal report (median of 24 earlier)
1.4M
Typical spread (median absolute deviation)
427K
How far from its usual level
+5.4
Same report last year
884K
History used
2,954 days
the 30 Jan 2026 report24 earlier reportsnormal: 1.4M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 26 Feb 2026
Ovid Therapeutics had 5.2M shares sold short in the 13 Feb 2026 report, 5.2× the same report last year.
This period
5.2M (the 13 Feb 2026 report)
Normal report (median of 24 earlier)
1.6M
Typical spread (median absolute deviation)
563K
How far from its usual level
+4.4
Same report last year
991K
History used
2,968 days
the 13 Feb 2026 report24 earlier reportsnormal: 1.6M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.
14 Nov 2025Institutional holdings change
saw 25 13F filers open a new position in the quarter ended 30 Sep 2025, 3.6× the same quarter last year.
Same quarter last year: 7; its normal quarter is 10.5.
See the evidence
This period
25 (the quarter ended 30 Sep 2025)
Normal quarter (median of 8 earlier)
10.5
Typical spread (median absolute deviation)
1.5
How far from its usual level
+4.8
Same quarter last year
7
History used
3,014 days
the quarter ended 30 Sep 20258 earlier quartersnormal: 10.5
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.
had 3.5M shares sold short in the 31 Oct 2025 report, 5.1× the same report last year.
Same report last year: 680K; its normal report is 1.1M.
See the evidence
This period
3.5M (the 31 Oct 2025 report)
Normal report (median of 24 earlier)
1.1M
Typical spread (median absolute deviation)
306K
How far from its usual level
+5.3
Same report last year
680K
History used
2,863 days
the 31 Oct 2025 report24 earlier reportsnormal: 1.1M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 3.8M shares sold short in the 15 Oct 2025 report, 6.3× the same report last year.
Same report last year: 607K; its normal report is 1.0M.
See the evidence
This period
3.8M (the 15 Oct 2025 report)
Normal report (median of 24 earlier)
1.0M
Typical spread (median absolute deviation)
300K
How far from its usual level
+6.3
Same report last year
607K
History used
2,847 days
the 15 Oct 2025 report24 earlier reportsnormal: 1.0M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 2.5M shares sold short in the 13 Jun 2025 report, 13% below the same report last year.
Same report last year: 2.9M; its normal report is 970K.
See the evidence
This period
2.5M (the 13 Jun 2025 report)
Normal report (median of 24 earlier)
970K
Typical spread (median absolute deviation)
236K
How far from its usual level
+4.4
Same report last year
2.9M
History used
2,723 days
the 13 Jun 2025 report24 earlier reportsnormal: 970K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 2.5M shares sold short in the 15 Dec 2023 report, 8.7× the same report last year.
Same report last year: 283K; its normal report is 498K.
See the evidence
This period
2.5M (the 15 Dec 2023 report)
Normal report (median of 24 earlier)
498K
Typical spread (median absolute deviation)
294K
How far from its usual level
+4.5
Same report last year
283K
History used
2,177 days
the 15 Dec 2023 report24 earlier reportsnormal: 498K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 2.3M shares sold short in the 30 Nov 2023 report, 8.5× the same report last year.
Same report last year: 271K; its normal report is 368K.
See the evidence
This period
2.3M (the 30 Nov 2023 report)
Normal report (median of 24 earlier)
368K
Typical spread (median absolute deviation)
165K
How far from its usual level
+7.9
Same report last year
271K
History used
2,162 days
the 30 Nov 2023 report24 earlier reportsnormal: 368K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 2.1M shares sold short in the 15 Nov 2023 report, 7.4× the same report last year.
Same report last year: 288K; its normal report is 305K.
See the evidence
This period
2.1M (the 15 Nov 2023 report)
Normal report (median of 24 earlier)
305K
Typical spread (median absolute deviation)
101K
How far from its usual level
+12.2
Same report last year
288K
History used
2,147 days
the 15 Nov 2023 report24 earlier reportsnormal: 305K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 2.0M shares sold short in the 31 Oct 2023 report, 7.2× the same report last year.
Same report last year: 278K; its normal report is 286K.
See the evidence
This period
2.0M (the 31 Oct 2023 report)
Normal report (median of 24 earlier)
286K
Typical spread (median absolute deviation)
75K
How far from its usual level
+15.6
Same report last year
278K
History used
2,132 days
the 31 Oct 2023 report24 earlier reportsnormal: 286K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 2.0M shares sold short in the 13 Oct 2023 report, 6.8× the same report last year.
Same report last year: 288K; its normal report is 286K.
See the evidence
This period
2.0M (the 13 Oct 2023 report)
Normal report (median of 24 earlier)
286K
Typical spread (median absolute deviation)
72K
How far from its usual level
+15.7
Same report last year
288K
History used
2,114 days
the 13 Oct 2023 report24 earlier reportsnormal: 286K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 2.1M shares sold short in the 29 Sep 2023 report, 7.3× the same report last year.
Same report last year: 283K; its normal report is 283K.
See the evidence
This period
2.1M (the 29 Sep 2023 report)
Normal report (median of 24 earlier)
283K
Typical spread (median absolute deviation)
66K
How far from its usual level
+18.2
Same report last year
283K
History used
2,100 days
the 29 Sep 2023 report24 earlier reportsnormal: 283K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 2.0M shares sold short in the 15 Sep 2023 report, 7.3× the same report last year.
Same report last year: 278K; its normal report is 280K.
See the evidence
This period
2.0M (the 15 Sep 2023 report)
Normal report (median of 24 earlier)
280K
Typical spread (median absolute deviation)
58K
How far from its usual level
+20.2
Same report last year
278K
History used
2,086 days
the 15 Sep 2023 report24 earlier reportsnormal: 280K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 2.1M shares sold short in the 31 Aug 2023 report, 7.2× the same report last year.
Same report last year: 288K; its normal report is 280K.
See the evidence
This period
2.1M (the 31 Aug 2023 report)
Normal report (median of 24 earlier)
280K
Typical spread (median absolute deviation)
55K
How far from its usual level
+22.1
Same report last year
288K
History used
2,071 days
the 31 Aug 2023 report24 earlier reportsnormal: 280K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Showing the newest 40 of 94 entries; narrow the window or the kind of data to see older ones.
Not listed: 131 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.
Identifiers and sources
How records are matched to this company, and what each source holds for it
Cik
0001636651
Ticker
OVID
Domain
ovidrx.com
Employer name
OVID THERAPEUTICS INC. (1 unverified)
Hq location
NY|NEW YORK|10001 (1 unverified)
Lobbying client
ovid therapeutics
Name
Ovid Therapeutics Inc.
DOL H-1B labor condition applications and PERM certifications15 data points5 Oct 2020 to 24 Jun 2024
Federal lobbying disclosures (LDA)2 records, 39 data points16 Oct 2019 to 31 Mar 2023
SEC Form 13F institutional holdings342 data points30 Jun 2017 to 30 Sep 2026
SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)152 records20 Jan 2017 to 10 Nov 2026
SEC XBRL company facts (revenue, capex, R&D, backlog...)621 data points31 Dec 2014 to 4 Nov 2026
SEC Form 4 insider transactions16 records, 52 data points28 Aug 2017 to 2 Mar 2026
FINRA short interest (twice monthly)624 data points29 Dec 2017 to 30 Oct 2026
FINRA daily short sale volume (off-exchange)4178 data points1 Aug 2018 to 20 Nov 2026